SOTIO is a biotechnology company developing innovative therapies that harness the immune system and focus primarily on immuno-oncology, effectively translating science into patient benefit. SOTIO is owned by the PPF Group, one of the largest investment groups in Central and Eastern Europe.

The most advanced project is proprietary platform of active cellular immunotherapy (ACI) based on dendritic cells for the treatment of cancer and autoimmune diseases. SOTIO is conducting multiple Phase I 
to Phase III clinical trials verifying the safety and efficacy of its DCVAC products.

SOTIO aims to become a mid-sized specialty pharma company that develops and commercializes innovative cancer therapeutics. We are building a diversified pipeline through internal development as well as strategic partnering. Our current licensing focus are innovative oncology therapies in advanced preclinical or clinical stage.